Carotenoid Demand Set to Rise as New Review Highlights Retinal Neuroprotection

London, United Kingdom

A comprehensive review of studies spanning 10 to 15 years, conducted by Polish researchers and published in *Nutrients*, reinforces the established efficacy of carotenoids, specifically lutein and zeaxanthin, in preserving retinal health. The analysis confirms these compounds' antioxidant, anti-inflammatory, and neuroprotective properties are crucial in mitigating photooxidative damage and maintaining retinal function. With an estimated rise to 61 million individuals living with blindness and over 834 million with moderate or severe visual impairment by 2050, the market for targeted eye health supplements is set for sustained growth, predicated on scientifically validated ingredients.

The review highlights lutein's capacity for blue light absorption, protecting against cellular damage by reducing light-induced reactive oxygen species (ROS) formation. Even at low concentrations, lutein directly scavenges free radicals, acting both preventatively and remedially. Furthermore, carotenoids modulate inflammatory pathways, support mitochondrial function, and stabilise the blood-retinal barrier, vital for ocular tissue homeostasis. For supplement manufacturers, these findings strengthen the scientific basis for eye health product claims, particularly for formulations targeting age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma.

Bioavailability remains a critical factor for product development. The review underscores that dietary fats, source material, and intestinal transport mechanisms (SR-BI, NPC1L1) directly influence carotenoid serum concentration and their distribution to ocular tissues. This necessitates careful formulation and potentially novel delivery systems to maximise biological activity. Beyond direct ocular benefits, the presence of lutein and zeaxanthin in the visual cortex suggests a broader functional relationship between ocular and central nervous system health, opening avenues for cognitive health co-claims.

Despite increasing evidence, the review identifies a need for further clinical trials to definitively establish therapeutic efficacy, optimal doses, and long-term safety, particularly concerning molecular processes like Nrf2, NF-κB, and MAPK pathway regulation. Most data supporting these molecular mechanisms derive from *in vitro* and animal models, with human clinical studies largely focusing on functional outcomes such as Macular Pigment Optical Density (MPOD), visual acuity, and contrast sensitivity. This gap presents both a challenge and an opportunity for brands to invest in advanced human clinical trials that correlate molecular biomarkers with visual outcomes, enabling more robust product differentiation.

What this means for United Kingdom

UK brand owners face increased demand for proven eye health solutions, requiring robust substantiation for products featuring lutein and zeaxanthin. Manufacturers must ensure formulations optimise bioavailability to meet consumer expectations and regulatory scrutiny from the FSA and MHRA. Competition will intensify, driving a need for differentiation through advanced clinical data beyond basic MPOD improvements, potentially exploring neuroprotective claims. Procurement leads should assess ingredient suppliers for transparency on bioavailability data and support for future research. Compliance teams must prepare for evolving substantiation requirements as scientific understanding of molecular mechanisms advances, impacting labelling and marketing strategies.

Source: Nutrients.

For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.